CMS has already finalized some prior authorization changes, and it has also proposed new drug-related rules that are not final yet. Here’s how the new timeline works, who may feel it, and what to do if care is delayed or denied.
The CDC says the Bicillin L-A shortage is still ongoing, and that matters because this is the preferred penicillin treatment for syphilis in pregnancy. Officials say limited supply should be preserved for pregnant patients whenever possible, while some areas may also use temporarily imported Lentocilin to help fill gaps.
The FDA has updated the meaning of “healthy” on packaged foods so the claim better matches current nutrition science and federal dietary guidance. The label may help shoppers compare products, but it is not a guarantee of low calories, minimal processing, or the best choice for every diet.
New CDC and CMS guidance keeps colorectal cancer screening front and center for adults ages 45 to 75. The main message is simple: screening is for people who do not have symptoms, and the right test depends on age, risk, access, and follow-up needs.
FDA is narrowing the path for compounded GLP-1 prescriptions as national supply stabilizes. Patients using these medicines should check whether their product is FDA-approved, compounded, or made from a bulk substance, because the rules and safety concerns are not the same.
Spring is a good time for adults to check vaccine records, especially after CDC updated pneumococcal and meningococcal guidance this year. Some adult vaccines are based on age, some on medical risk, and some need regular timing such as flu shots or a seasonal COVID-19 review.
A large U.S. trial is putting risk-based breast cancer screening in the spotlight. The main takeaway for readers: it looks promising, but it has not replaced current screening guidance, and people should not change their schedule on their own.
A large U.S. trial suggests breast cancer screening could one day be tailored to a woman’s individual risk instead of using the same schedule for everyone. The approach looked promising, but experts say it is not ready to replace routine screening on its own.
CMS and FDA have announced RAPID, a new pathway meant to shorten Medicare coverage decisions for certain breakthrough medical devices. The change could help some patients get access sooner, but it applies only to a narrow set of devices and still depends on formal federal review.
A late-April FDA recall of B. Braun Lactated Ringer’s Injection is mainly a hospital supply issue, but it can matter for patients who may have received the affected IV fluid. The key questions are whether a facility used one of the recalled lots, whether any symptoms followed, and how to report concerns.
U.S. measles activity remains elevated, and public health officials say the disease is still spreading in outbreaks in multiple states. For readers, the practical takeaway is simple: know the early symptoms, check vaccination status, and act quickly after a known exposure. Measles is highly contagious, and the first signs can look like a routine viral illness before the rash appears. If you think you were exposed, call ahead before visiting a clinic or emergency department so staff can reduce the chance of exposing others.
CDC refreshed its nutrition pages in March and April 2026 with a simple message: most Americans still get too much added sugar, and sugary drinks are a major source. The agency’s updated label guidance is meant to help families spot added sugars, compare packaged foods, and make small swaps that can lower intake.
CMS and the FDA have created a new Medicare coverage pathway aimed at speeding access to certain breakthrough medical devices. The first practical effect is a faster route to a proposed Medicare coverage decision after FDA authorization, but many details still depend on implementation.
A multistate E. coli outbreak linked to raw cheddar cheese and raw milk has ended, but the recall is a reminder that unpasteurized dairy can carry serious food-safety risks — especially for young children and other people more likely to get very sick. Here’s what happened, what to check at home, and when symptoms need urgent care.
RSV is still showing up in parts of the United States even as overall respiratory illness remains very low. CDC says the season arrived later than expected in many regions, which is why some communities may still see RSV activity in May. For older adults and others at higher risk, now is still a good time to check vaccine status and watch for warning signs.
The FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from a federal list used by some outsourcing compounders. If finalized, the change could narrow access to some compounded GLP-1 weight-loss products. The proposal does not change the approval status of brand-name obesity medicines. It does raise fresh questions about access, quality, and how compounded versions differ from FDA-approved drugs.
The FDA says thousands of clinical trial results still are not being reported as required, leaving gaps that can make medicines and devices look better understood than they are. For readers, the key takeaway is simple: one study rarely tells the whole story, especially when negative or inconclusive findings never make it into the public record.
CMS has proposed extending its electronic prior-authorization rules to prescription drugs, with comments open through June 15, 2026. If finalized, the change could reduce paperwork and speed some decisions, but prior authorization would still exist and results could vary by plan.
The FDA says B. Braun has recalled two lots of Lactated Ringer’s Injection after particulate matter was found in the solution. The recall mainly affects hospitals, clinics, and other facilities that stocked the affected lots, but patients who recently received this IV fluid may want to check with the treating facility if they have concerns.
FDA’s updated “healthy” claim can help shoppers compare packaged foods, but it is only one clue. Readers still need to check sodium, added sugars, saturated fat, and serving size on the Nutrition Facts panel before treating the label as a health verdict.
CMS has proposed new rules that would push more drug prior authorizations into electronic workflows and set tighter decision timelines for several federally regulated health plans. If finalized, the changes could affect Medicare Advantage, Medicaid, CHIP, and ACA Marketplace plans, but details would still vary by plan and state.
The FDA says a Class I recall covers TRUE METRIX blood glucose monitoring systems because an E-5 error code can mean either very high blood sugar or a strip problem. That mix-up can delay treatment or lead to the wrong response, so users should know the warning signs, confirm what device they have, and check the latest FDA guidance.
End of content
End of content
